Servier Expands Partnership with Google Cloud to Accelerate Pharmaceutical R&D
Servier initially signed a five-year agreement with Google Cloud in August 2022, focusing on technology infrastructure.
Servier, an international pharmaceutical group, has extended its partnership with Google Cloud to enhance pharmaceutical research and development (R&D).
The expanded five-year agreement will leverage Google Cloud’s artificial intelligence (AI) capabilities to analyze large volumes of medical data in real time and advance drug discovery and development processes.
The partnership focuses on using Google Cloud's AI offerings to address key challenges in pharmaceutical R&D.
Servier has already identified around 60 generative AI use cases, including the identification of new therapeutic targets, drug screening, understanding the biological evolution of diseases and medications, and optimizing drug formulations.
The adoption of these AI tools aims to accelerate time to market and enhance the precision of research outcomes.
Claude Bertrand, Executive Vice President of R&D and Chief Scientific Officer at Servier, said, “The combination of scientific innovation and advanced digital technologies, especially artificial intelligence, enables us to bring innovative treatments to patients more quickly and deliver more personalized solutions. This enhanced collaboration with Google Cloud allows us to harness AI's full potential to reach scientific conclusions faster and improve the productivity of our R&D.”
Servier has already begun integrating Google Cloud AI technologies, including Gemini large language models (LLMs), into its operations.
Shweta Maniar, Global Director of Healthcare & Life Sciences at Google Cloud, said, “Servier is transitioning from experimentation to production with a clear focus on ethics, confidentiality, and security. This collaboration will advance research and treatment for various diseases.”
Servier initially signed a five-year agreement with Google Cloud in August 2022, focusing on technology infrastructure.
The renewed partnership extends their collaboration for another five years, with both companies aiming to leverage AI advancements for innovative breakthroughs in healthcare.
Stay tuned for more such updates on Digital Health News.
